Mantle zone lymphoma is a relatively rare and aggressive type of non-Hodgkin lymphoma (NHL) that originates from the mantle zone of the lymph nodes and other lymphoid tissues. The mantle zone is a region of lymphoid follicles located just beneath the outer layer (mantle) of the lymph node.
In mantle zone lymphoma, there is an abnormal accumulation of B-cells in the mantle zone, which then begin to grow and divide uncontrollably. This leads to the development of tumor masses primarily in the lymph nodes, but it can also spread to other organs and tissues such as the bone marrow, spleen, gastrointestinal tract, and skin.
Patients with mantle zone lymphoma usually present with symptoms such as painless swelling of the lymph nodes, night sweats, fatigue, unexplained weight loss, and occasionally fever. Diagnosis of mantle zone lymphoma requires a combination of clinical evaluation, physical examination, imaging tests, and a biopsy of the affected tissue for histological analysis.
Treatment options for mantle zone lymphoma typically involve multidrug chemotherapy regimens, combined with immunotherapy and, in some cases, radiation therapy. Stem cell transplantation may be considered for eligible patients. Prognosis for mantle zone lymphoma varies depending on various factors, including the extent of the disease at diagnosis, the patient's overall health, and response to treatment. While the disease is often aggressive, advances in targeted therapies have improved outcomes for some patients.
In summary, mantle zone lymphoma is an uncommon type of non-Hodgkin lymphoma characterized by the abnormal growth of B-cells in the mantle zone of lymphoid tissues. It usually requires intensive treatment and close medical monitoring.
